Skip to main content

Table 1 Baseline characteristics of the study sample

From: Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study

Characteristics COPD (n = 200) No COPD (n = 201) P-value
Age, years 66 (61-70) 65 (61-70) 0.258
Male sex 178 (89) 172 (86) 0.369
BMI (kg/m2) 27 (24-31) 28 (25-30) 0.508
Current smoker 97 (49) 101 (50) 0.766
Pack-years of smoking 48 (39-60) 40 (33-50) <0.001
FEV1, % predicted 54 (42-65) 95 (88-105) <0.001
DLCO, % predicted 76 (58-86) 96 (86-108) <0.001
Chronic mucous hypersecretion 116 (58) 46 (23) <0.001
Chronic cor pulmonale 47 (24) 0 (0) <0.001
Emphysema 87 (44) 0 (0) <0.001
Comorbidity    
Systemic arterial hypertension 95 (48) 75 (37) 0.043
Coronary artery disease 59 (30) 55 (27) 0.659
Heart failure 23 (12) 13 (6.5) 0.083
Dilated cardiomyopathy 6 (3) 6 (3) 1.000
Left heart valvular disease 8 (4) 5 (2.5) 0.416
Chronic atrial fibrillation 10 (5) 7 (3.5) 0.470
Prior stroke 2 (1) 3 (1.5) 1.000
Prior PE or DVT 5 (2.5) 3 (1.5) 0.503
Renal failure 0 (0) 0 (0) 1.000
Diabetes mellitus 22 (11) 30 (15) 0.298
Dyslipidemia 61 (31) 74 (37) 0.205
Thyroid dysfunction 18 (9) 11 (5.5) 0.183
Chronic hepatitis C 7 (3.5) 9 (4.5) 0.799
Therapy    
Inhaled bronchodilators 139 (70) 0 (0) <0.001
Inhaled corticosteroids 128 (64) 0 (0) <0.001
Oral theophylline 48 (24) 0 (0) <0.001
Long-term oxygen 7 (3.5) 0 (0) 0.007
Cardiovascular drugs 122 (61) 108 (54) 0.158
Diuretics 52 (26) 30 (15) 0.006
Warfarin 15 (8) 10 (5) 0.311
Statins 37 (19) 47 (23) 0.269
Oral hypoglicemic drugs/insulin 17 (9) 21 (10) 0.609
Thyroid replacement therapy 7 (3.5) 4 (2) 0.380
  1. Data are reported as median (interquartile range), or number (%).
  2. Definitions of abbreviations: BMI = body mass index; FEV1 = forced expiratory volume in one second; DLCO = diffusing capacity of the lung for carbon monoxide; PE = pulmonary embolism; DVT = deep vein thrombosis.